MAHONEY-SANCHEZ, L., H. BOUCHAOUI, S. AYTON, D. DEVOS, JA. DUCE and JC. DEVEDJIAN. Ferroptosis and its potential role in the physiopathology of Parkinson's Disease. PROGRESS IN NEUROBIOLOGY. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD, 2021, vol. 196, January 2021, p. 1-12. ISSN 0301-0082. Available from: https://dx.doi.org/10.1016/j.pneurobio.2020.101890.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Ferroptosis and its potential role in the physiopathology of Parkinson's Disease
Authors MAHONEY-SANCHEZ, L. (guarantor), H. BOUCHAOUI, S. AYTON, D. DEVOS, JA. DUCE and JC. DEVEDJIAN.
Edition PROGRESS IN NEUROBIOLOGY, OXFORD, PERGAMON-ELSEVIER SCIENCE LTD, 2021, 0301-0082.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30230 Other clinical medicine subjects
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW FAIRPARK II
Impact factor Impact factor: 10.885
RIV identification code RIV/00216224:14110/21:00124114
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.pneurobio.2020.101890
UT WoS 000604785900006
Keywords (in Czech) Parkinson's Disease; Non apoptotic cell death; Ferroptosis; Iron metabolism; Oxidative stress; Lipid peroxidation; Alpha synuclein
Keywords in English Parkinson's Disease; Non apoptotic cell death; Ferroptosis; Iron metabolism; Oxidative stress; Lipid peroxidation; Alpha synuclein
Tags Excelence Science, International, MU, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 3/5/2022 08:49.
Abstract
Parkinson's Disease (PD) is a common and progressive neurodegenerative disorder characterised by motor impairments as well as non-motor symptoms. While dopamine-based therapies are effective in fighting the symptoms in the early stages of the disease, a lack of neuroprotective drugs means that the disease continues to progress. Along with the traditionally recognised pathological hallmarks of dopaminergic neuronal death and intracellular a-synuclein (alpha-syn) depositions, iron accumulation, elevated oxidative stress and lipid peroxidation damage are further conspicuous features of PD pathophysiology. However, the underlying mechanisms linking these pathological hallmarks with neurodegeneration still remain unclear. Ferroptosis, a regulated iron dependent cell death pathway involving a lethal accumulation of lipid peroxides, shares several features with PD pathophysiology. Interestingly, alpha-syn has been functionally linked with the metabolism of both iron and lipid, suggesting a possible interplay between dysregulated alpha-syn and other PD pathological hallmarks related to ferroptosis. This review will address the importance for understanding these disease mechanisms that could be targeted therapeutically. Anti-ferroptosis molecules are neuroprotective in PD animal models and the anti-ferroptotic iron chelator, deferiprone, slowed disease progression and improved motor function in two independent clinical trials for PD. An ongoing larger multi-centre phase 2 clinical trial will confirm the therapeutic potential of deferiprone and the relevance of ferroptosis in PD. This review addresses the known pathological features of PD in relation to the ferroptosis pathway with therapeutic implications of targeting this cell death pathway.
Links
90128, large research infrastructuresName: CZECRIN III
PrintDisplayed: 27/7/2024 13:33